Thomas J. Schuetz, MD, PhD
About Us
Current Events
Past Events
Video Gallery
Policy & Reports
Media Coverage
Contact Us
Thomas J. Schuetz, MD, PhD
Co-founder and Chief Executive Officer
Compass Therapeutics

Dr. Schuetz has over 20 years of experience in oncology, biopharmaceutical drug development, and life science venture investing.

Dr. Schuetz co-founded Compass in 2014 following conceptual discussions while he was Venture Partner at Orbimed. As a physician-scientist and serial entrepreneur, he aspired to create an antibody therapeutic company based on novel biology, protein engineering and key medical insights gathered throughout his career. While at OrbiMed, Tom co-founded Audentes, now a publicly traded biotechnology company where he remains a Director. Also at OrbiMed, he was responsible for the investments in Enobia, Relypsa, and Arteaus, where he served as a Director at each of those companies. Enobia was acquired by Alexion Pharmaceuticals in 2011, Relypsa was acquired by Galenica in 2016, and Arteaus was acquired by Lilly in 2014.  Dr. Schuetz has multiple years of clinical strategy, development, and operations experience including roles as Chief Medical Officer of Therion Biologics Corporation, a cancer vaccine company, and as the Vice President of Clinical Affairs at Transkaryotic Therapies, a company acquired by Shire.

Dr. Schuetz completed his medical training at Massachusetts General Hospital, where he served as the Chief Medical Resident, and completed his Medical Oncology Fellowship at the Dana-Farber Cancer Institute. Dr. Schuetz holds a BS in Chemistry from Xavier University, an MD from Harvard Medical School and a PhD in Genetics from Harvard University. Dr. Schuetz is Board Certified in Medical Oncology.

© 2007 - USA India Chamber of Commerce Home | About us | Policy | Events | Photo Gallery | Awards | Media Coverage | Legal | Contact us